Integrating Novel Classes of Immunotherapy Into Treatment Paradigms in Advanced/Metastatic Melanoma

Integrating Novel Classes of Immunotherapy Into Treatment Paradigms in Advanced/Metastatic Melanoma is organized by Prime Education, LLC.

Broadcast Date: Thursday, Jun 15, 2023, at 2:00 PM Eastern (11:00 AM Pacific)

Overview:
Among oncologists caring for melanoma patients, gaps have been identified in knowledge related to clinical data on novel therapies, how to sequence therapies, and the identification of appropriate patients associated with novel therapies.

Join us for the final webinar of this two-part webinar series for an in-depth review of:

• Patient and disease factors impacting treatment decision-making
• Selection and sequencing of novel therapies for advanced melanoma
• Best practices for referral and coordination of care during tumor-infiltrating lymphocyte (TIL) therapy.

This webinar is delivered in partnership with the Melanoma Research Alliance.

Learning Objectives:

• Assess patient-specific factors that guide the use of adoptive cellular therapy and individualize treatment decision-making for patients with advanced/metastatic melanoma
• Employ evidence-based strategies to integrate new and emerging immune checkpoint inhibitors and adoptive T-cell therapies into current clinical paradigms for advanced/metastatic melanoma
• Develop interprofessional strategies to support prompt referral and optimize quality care and outcomes for patients with advanced and metastatic melanoma

Agenda:

1. Overview of Recommended First- and Later-Line Therapies for Advanced/Metastatic Melanoma
2. Examining the Placement of Immune Checkpoint Inhibitors (ICI) and Tumor Infiltrating Lymphocyte (TIL) Therapies in the Evolving Melanoma Treatment Paradigm
3. Using Patient- and Tumor-Specific Factors to Proactively Identify Appropriate Patients for ICI and TIL Therapies
4. Expert Discussion of Best Practices for Referral and Interprofessional Coordination of Care during TIL Therapy in Melanoma